Therapeutic agent

N-Acetylcysteine (NAC)

Also known as: N-Acetylcysteine (NAC)

PreliminaryEvidence level
4Registered trials
5Conditions
3Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Immunomodulatory
Safety
Excellent safety profile. GI upset (nausea, vomiting, diarrhea) at high doses. Rare bronchospasm with inhalation. Safe in pregnancy at standard doses.
Dosing
600–1800 mg/day divided doses (e.g. 600 mg TID); durations in studies 4–12 weeks.
NAC 600-1800mg/day. Glutathione/antioxidant support; studied for fatigue/oxidative stress in Long COVID/ME-CFS. Good safety profile; small positive studies.

Clinical Trials

4 trial(s) registered

NCT IDTitlePhaseStatus
NCT05371288The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19Early phase 1Withdrawn
NCT04542161Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue SyndromePhase 2Active, not recruiting
NCT03502044New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic FaNot applicableUnknown status
NCT01154647Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity SyndromesNot applicableUnknown status

Key Studies / References